Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019

L. Merdrignac, F. Aït El Belghiti, E. Pandolfi, L. Acosta, K. Fabiánová, A. Habington, M. García Cenoz, H. Bøås, J. Toubiana, AE. Tozzi, I. Jordan, J. Zavadilová, N. O'Sullivan, A. Navascués, E. Flem, I. Croci, M. Jané, P. Křížová, S. Cotter, L....

. 2024 ; 42 (9) : 2370-2379. [pub] 20240311

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014386
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Family Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci

Odkazy

PubMed 38472070
DOI 10.1016/j.vaccine.2024.02.090
Knihovny.cz E-zdroje

BACKGROUND: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year. METHODS: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it). RESULTS: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36-73). Adjusted VE was 48 % (95 %CI: 5-71) for dose one (416 eligible infants) and 76 % (95 %CI: 43-90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose. CONCLUSIONS: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014386
003      
CZ-PrNML
005      
20240905133554.0
007      
ta
008      
240725s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2024.02.090 $2 doi
035    __
$a (PubMed)38472070
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Merdrignac, Lore $u Epidemiology Department, Epiconcept, Paris, France. Electronic address: l.merdrignac@epiconcept.fr
245    10
$a Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019 / $c L. Merdrignac, F. Aït El Belghiti, E. Pandolfi, L. Acosta, K. Fabiánová, A. Habington, M. García Cenoz, H. Bøås, J. Toubiana, AE. Tozzi, I. Jordan, J. Zavadilová, N. O'Sullivan, A. Navascués, E. Flem, I. Croci, M. Jané, P. Křížová, S. Cotter, L. Fernandino, T. Bekkevold, C. Muñoz-Almagro, S. Bacci, P. Kramarz, E. Kissling, C. Savulescu, Renacoq Group, PERTINENT Group
520    9_
$a BACKGROUND: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year. METHODS: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it). RESULTS: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36-73). Adjusted VE was 48 % (95 %CI: 5-71) for dose one (416 eligible infants) and 76 % (95 %CI: 43-90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose. CONCLUSIONS: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three.
650    _2
$a kojenec $7 D007223
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a pertuse $x epidemiologie $x prevence a kontrola $7 D014917
650    _2
$a sentinelová surveillance $7 D018571
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a pertusová vakcína $7 D010567
650    _2
$a vakcinace $x metody $7 D014611
650    _2
$a hospitalizace $7 D006760
655    _2
$a časopisecké články $7 D016428
700    1_
$a Aït El Belghiti, Fatima $u Direction des maladies infectieuses, Santé Publique France, Paris, France
700    1_
$a Pandolfi, Elisabetta $u Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy
700    1_
$a Acosta, Lesly $u Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain; Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya- BarcelonaTech (UPC), Barcelona, Spain
700    1_
$a Fabiánová, Kateřina $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Habington, Adele $u Children's Health Ireland, Crumlin, Dublin, Ireland
700    1_
$a García Cenoz, Manuel $u Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
700    1_
$a Bøås, Håkon $u Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway
700    1_
$a Toubiana, Julie $u Biodiversité et Epidémiologie des bactéries et pathogènes, Institut Pasteur, Paris, France; National Reference Center for Whooping Cough and Other Bordetella Infections, Institut Pasteur, Paris, France
700    1_
$a Tozzi, Alberto E $u Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy
700    1_
$a Jordan, Iolanda $u Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; University of Barcelona, Barcelona, Spain
700    1_
$a Zavadilová, Jana $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a O'Sullivan, Niam $u Children's Health Ireland, Crumlin, Dublin, Ireland
700    1_
$a Navascués, Ana $u Hospital Universitario Navarra, Pamplona
700    1_
$a Flem, Elmira $u Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway
700    1_
$a Croci, Ilena $u Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy
700    1_
$a Jané, Mireia $u Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; University of Barcelona, Barcelona, Spain
700    1_
$a Křížová, Pavla $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Cotter, Suzanne $u Health Protection Surveillance Centre, Dublin, Ireland
700    1_
$a Fernandino, Leticia $u Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain
700    1_
$a Bekkevold, Terese $u Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway
700    1_
$a Muñoz-Almagro, Carmen $u Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain
700    1_
$a Bacci, Sabrina $u European Centre for Diseases Control and Prevention, Stockholm, Sweden
700    1_
$a Kramarz, Piotr $u European Centre for Diseases Control and Prevention, Stockholm, Sweden
700    1_
$a Kissling, Esther $u Epidemiology Department, Epiconcept, Paris, France
700    1_
$a Savulescu, Camelia $u Epidemiology Department, Epiconcept, Paris, France
710    2_
$a Renacoq Group
710    2_
$a PERTINENT Group
773    0_
$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 42, č. 9 (2024), s. 2370-2379
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38472070 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133548 $b ABA008
999    __
$a ok $b bmc $g 2143888 $s 1226252
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 42 $c 9 $d 2370-2379 $e 20240311 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a Pubmed-20240725
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace